Myeloma stem cells in autografting in multiple myeloma.
Autologous transplantation has been used increasingly over the last 10 years for the treatment of multiple myeloma. As is the case in other cancers treated by high-dose therapy and stem cell rescue, the contribution of occult tumor cells in the graft to relapse posttransplant remains to be resolved. In this report, we review the biology and differentiation of plasma cells in the context of their significance as an origin of relapse in multiple myeloma.
To
L B
LB
Division of Haematology, Hanson Centre for Cancer Research, Adelaide, S. Australia.
Horvath
N
N
Dyson
P
P
Henry
J
J
Sykes
P
P
Brisco
M
M
Morley
A
A
Bennetts
B
B
D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000473:pathology / Q000628:therapy; D014411:Neoplastic Stem Cells / Q000473:pathology*; D012008:Recurrence; D014182:Transplantation, Autologous